Acute Left Ventricular Dysfunction following Gemtuzumab Ozogamicin in Two Pediatric AML Patients

Kevin O. McNerney, Katelyn Oranges, Alix E. Seif, Benjamin Oshrine, Bonnie Ky, Kimberly Y. Lin, Kelly D. Getz, Richard Aplenc

Research output: Contribution to journalArticlepeer-review

Abstract

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic conjugate with proven efficacy in pediatric and adult patients with CD33+acute myeloid leukemia. Adverse effects commonly associated with GO include hyperbilirubinemia, elevated transaminases, and sinusoidal obstruction syndrome. Cardiotoxicity has not been a commonly described adverse event. We describe 2 pediatric patients with relapsed/refractory acute myeloid leukemia who received fractionated GO monotherapy and subsequently developed severe acute left ventricular dysfunction. Both patients achieved remission, recovered cardiac function with medical therapy, and tolerated subsequent stem cell transplantation.

Original languageEnglish (US)
JournalJournal of Pediatric Hematology/Oncology
DOIs
StateAccepted/In press - 2021
Externally publishedYes

Keywords

  • acute myeloid leukemia
  • cardio-oncology
  • cardiotoxicity
  • gemtuzumab ozogamicin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Acute Left Ventricular Dysfunction following Gemtuzumab Ozogamicin in Two Pediatric AML Patients'. Together they form a unique fingerprint.

Cite this